Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons

Brain Research

Volumn 989, Issue 2, 2003, Pages 187-195

  Cleren, Carine ^a   Naudin, Bertrand ^a   Costentin, Jean ^a  

^a U de Neuropsychopharmacologie Exp   (France)

Author keywords

1 Methyl 4 phenylpyridinium; 6 Hydroxydopamine; Hypothermia; Mouse; Reserpine; Tetrabenazine; Vesicular monoamine transporter type 2

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; NEUROTOXIN; OXIDOPAMINE; RESERPINE; TETRABENAZINE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; ELECTRIC POTENTIAL; EXPERIMENTATION; FORCED SWIMMING TEST; HYPOTHERMIA; INHIBITION KINETICS; LOW TEMPERATURE; MALE; MEDICAL LITERATURE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OBSERVATION; PRIORITY JOURNAL;

EID: 0141861947     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)03333-X     Document Type: Article

References (46)

1. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65:(2):2001;135-172.
2. Breese G.R., Traylor T.D. Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br. J. Pharmacol. 42:(1):1971;88-99.
3. Busto R., Dietrich W.D., Globus M.Y., Valdes I., Scheinberg P., Ginsberg M.D. Small differences in intraischemic brain temperature critically determine the extent of ischemic neuronal injury. J. Cereb. Blood Flow Metab. 7:(6):1987;729-738.
4. Cooper D.R., Marrel C., van de Waterbeemd H., Testa B., Jenner P., Marsden C.D. L-dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice. J. Pharm. Pharmacol. 39:(10):1987;809-818.
5. Curtius H.C., Wolfensberger M., Steinmann B., Redweik U., Siegfried J. Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J. Chromatogr. 99:1974;529-540.
6. + administered centrally in mice. Neuropharmacology. 36:(7):1997;993-997.
7. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32:(6):1992;804-812.
8. +-induced effects on body temperature exhibit age- and strain-dependence in mice. Brain Res. 688:(1-2):1995;161-170.
9. Gainetdinov R.R., Fumagalli F., Wang Y.M., Jones S.R., Levey A.I., Miller G.W., Caron M.G. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 70:(5):1998;1973-1978.
10. German D.C., Liang C.L., Manaye K.F., Lane K., Sonsalla P.K. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. Neuroscience. 101:(4):2000;1063-1069.
11. Giachetti A., Hollenbeck R.A., Shore P.A. Localization and binding of reserpine in the membrane of adrenomedullary amine storage granules. Naunyn Schmiedebergs Arch. Pharmacol. 283:(3):1974;263-275.
12. Giovanni A., Sieber B.A., Heikkila R.E., Sonsalla P.K. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 257:(2):1991;691-697.
13. Glinka Y., Tipton K.F., Youdim M.B. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J. Neurochem. 66:(5):1996;2004-2010.
14. Glowinski J., Iversen L.L. Regional studies of catecholamines in the rat brain: I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]L-DOPA in various regions of the brain. J. Neurochem. 13:1966;655-669.
15. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. 12:1957;12-15.
16. Henry J.P., Scherman D. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem. Pharmacol. 38:(15):1989;2395-2404.
17. Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D., Youdim M.B. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59:(3):1992; 1168-1171.
18. Jellinger K., Linert L., Kienzl E., Herlinger E., Youdim M.B. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J. Neural Transm. 46:(Suppl.):1995;297-314.
19. Jenner P., Dexter D.T., Sian J., Schapira A.H., Marsden C.D. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 32:(Suppl.):1992;S82-87.
20. Karoum F., Chrapusta S.J., Egan M.F., Wyatt R.J. Absence of 6-hydroxydopamine in the rat brain after treatment with stimulants and other dopaminergic agents: a mass fragmentographic study. J. Neurochem. 61:(4):1993;1369-1375.
21. Langston J.W., Irwin I., Ricaurte G.A. Neurotoxins, parkinsonism and Parkinson's disease. Pharmacol. Ther. 32:(1):1987;19-49.
22. Leroux-Nicollet I., Panissaud C., Costentin J. Involvement of norepinephrine neurons in the hypothermia induced by intracerebroventricular administration of 6-hydroxydopamine in mice, evidenced by antidepressants. J. Neural Transm. 74:(1):1988;17-27.
23. + toxicity encodes a vesicular amine transporter. Cell. 70:(4):1992;539-551.
24. Liu Y., Roghani A., Edwards R.H. Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. Proc Natl Acad Sci USA. 89:(19):1992;9074-9078.
25. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
26. Masuo Y., Pelaprat D., Scherman D., Rostene W. [3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum. Neurosci. Lett. 114:(1):1990;45-50.
27. + levels and enhances toxicity to dopamine neurons in MPTP-treated mice. Brain Res. 790:(1-2):1998;264-269.
28. Naudin B., Bonnet J.J., Costentin J. Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice. Brain Res. 701:(1-2):1995;151-157.
29. L. Naudon, I. Leroux-Nicollet, R. Raisman-Vozari, D. Botton, J. Costentin, Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and of the membrane dopamine uptake complex. Synapse (21) (1995) 29-36.
30. L. Naudon, R. Raisman-Vozari, R.H. Edwards, I. Leroux-Nicollet, D. Peter, Y. Liu, J. Costentin, Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites. Eur. J. Neurosci. (4) (1996) 842-846.
31. Reinhard J.F. Jr., Daniels A.J., Viveros O.H. Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in the mouse; evidence for subcellular sequestration as basis for cellular resistance to the toxicant. Neurosci. Lett. 90:(3):1988;349-353.
32. Scherman D., Jaudon P., Henry J.P. Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine. Proc. Natl. Acad. Sci. USA. 80:(2):1983;584-588.
33. Scherman D. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J. Neurochem. 47:(2):1986;331-339.
34. Schmidt N., Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm. 108:(11):2001;1263-1282.
35. Schuldiner S. A molecular glimpse of vesicular monoamine transporters. J. Neurochem. 62:(6):1994;2067-2078.
36. Senoh S., Witkop B. Non enzymatic conversions of dopamine to norepinephrine and trihydroxyphenethylamine. J. Am. Chem. Soc. 81:1959;6222-6231.
37. Slivka A., Cohen G. Hydroxyl radical attack on dopamine. J. Biol. Chem. 260:(29):1985;15466-15472.
38. Staal R.G., Sonsalla P.K. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J. Pharmacol. Exp. Ther. 293:(2):2000;336-342.
39. Stitzel R.E. The biological fate of reserpine. Pharmacol. Rev. 28:(3):1976;179-208.
40. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., Jackson-Lewis V., Przedborski S., Uhl G.R. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. USA. 94:(18):1997;9938-9943.
41. Tetrud J.W., Langston J.W., Garbe P.L., Ruttenber A.J. Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurology. 39:(11):1989;1483-1487.
42. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61:(4):1993;1191-1206.
43. Tonon G., Saiani L., Spano P.F., Trabucchi M. Differential effect of reserpine on dopaminergic receptor function in rat substantia nigra and caudate nucleus. Brain Res. 160:(3):1979;553-558.
44. Vaccari A., Saba P. The tyramine-labelled vesicular transporter for dopamine: a putative target of pesticides and neurotoxins. Eur. J. Pharmacol. 292:(3-4):1995;309-314.
45. Vaccari A., Saba P.L., Gessa G.L., Del Zompo M. Differential interaction of 1-methyl-4-phenylpyridinium ion with the putatively vesicular binding site of [3H]tyramine in dopaminergic and nondopaminergic brain regions. J. Neurochem. 60:(2):1993;758-760.
46. Xie T., McCann U.D., Kim S., Yuan J., Ricaurte G.A. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J. Neurosci. 20:(20):2000;7838-7845.